The primary positive outcome is a reduction in parent-reported sleep problem scores, indicating improved sleep quality and potentially better seizure control and overall child well-being.
Improvement in sleep quality, reduction in insomnia symptoms, and enhanced overall well-being as measured by validated self-reported scales.
Significant associations were found between sleep disturbance and cognitive impairment in mood disorders, with improvements in sleep linked to better cognitive performance in BD.
86% of children experienced improvements in sleep onset, 54% in sleep duration, and 45% in night awakenings. Additionally, melatonin improved daytime behaviors in over 28% of the children.
Exercise training alone led to moderate improvements in insomnia severity, while the combination of CBTi and exercise training resulted in larger reductions in insomnia symptoms, with effect sizes comparable to CBTi alone in other populations.
Increased total sleep time, decreased sleep onset latency, and reduced waking after sleep onset in both mice and children with insomnia.
All treatment groups (25, 50, and 100 mg TruCBN™) and the 4 mg melatonin group showed significant improvement in sleep quality compared to placebo. Participants taking 100 mg TruCBN™ experienced a larger decrease in stress.
Participants using the botanical supplement experienced significant improvements in sleep disturbance, anxiety, stress, and overall well-being compared to the placebo group.
The intervention demonstrated feasibility and acceptability, leading to reduced bedtime procrastination and improved sleep quality. Increased self-compassion was associated with better emotion regulation, which contributed to the reduction in procrastination behaviors.
Successful OSA management positively impacted systolic blood pressure (SBP) in hypertensive patients, with CPAP success leading to a greater improvement in SBP z-score percentile compared to surgical treatment.
Significant improvement in sleep quality was observed, with the Pittsburgh Sleep Quality Index (PSQI) score decreasing from 9.42 to 6.26 (p<0.001). Heart rate during sleep decreased significantly by 1.3 bpm in the first week (p=0.045).
Approximately two-thirds of patients with ASD experienced improvement in sleep problems when treated with melatonin, indicating its effectiveness in this population.
Children with insomnia exhibited higher rates of healthcare utilization, including increased hospitalizations and emergency room visits. Treating insomnia may lead to broader clinical improvements beyond sleep disturbances.
Insomnia, poor sleep quality, and short sleep duration were associated with increased prevalence of PASC, suggesting that improving sleep may lower the risk of developing these sequelae.
Participants using the dayzz app showed increased healthy sleep behaviors, longer sleep duration, improved sleep quality, reduced presenteeism, and lower healthcare utilization compared to the control group.
The sleep lotion significantly increased salivary melatonin levels by up to approximately 1000 fold compared to the placebo, and improved sleep quality in a subsample of poor sleepers.
Improved sleep quality and reduced sleep deprivation among students, particularly those who received tailored circadian hygiene advice. Early-chronotype students demonstrated better academic performance compared to later chronotype students.
The study aims to demonstrate improvements in sleep duration, quality, employee mood, and overall productivity, as well as reductions in absenteeism and presenteeism among users of the app.
Caffeine intake resulted in a dose-dependent reduction in EEG delta activity and heart rate, while increasing heart rate variability during NREM sleep, indicating enhanced parasympathetic activity.
The study indicates a significant increase in the prevalence of sleep disorders, with insomnia being the most common, suggesting a growing recognition of sleep disorders as a major health issue that requires attention and treatment.
Identified four typologies of activity-related behaviours, highlighting the need for interventions to prevent unhealthy lifestyle transitions.
Potential improvements in sleep duration, quality, and overall health and well-being of adolescents in LMICs.
Unmedicated patients showed flatter aperiodic slopes compared to controls, indicating altered neural dynamics. After 7 days of antidepressant treatment, slopes were steeper, suggesting a change in neural activity. Increased variability of slopes in both unmedicated and medicated states indicates unstable neural activity, which may reflect the underlying pathology of MDD.